Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses

• Autori principali: Pedro Barrios-Bernal (Autore), Zyanya Lucia Zatarain-Barrón (Autore), Norma Hernández-Pedro (Autore), Mario Orozco-Morales (Autore), Alejandra Olivera-Ramírez (Autore), Federico Ávila-Moreno (Autore), Ana Laura Colín-González (Autore), Andrés F. Cardona (Autore), Rafael Rosell (Autore), Oscar Arrieta (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2022-06-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Metformin has been under basic and clinical study as an oncological repurposing pharmacological agent for several years, stemming from observational studies which consistently evidenced that subjects who were treated with metformin had a reduced risk for development of cancer throughout their lives,...